Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.
Patients with autoimmune and rheumatic diseases who received antiviral therapy for COVID-19 demonstrated reduced incidence of ...
Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback